The metastatic lesion was determined to be HCC, so they were transitioned to HCC-specific therapy and were treated with (1) GEMOX (gemcitabine hydrochloride/oxaliplatin)/sorafenib, (2) TARE, (3) atezolizumab/bevacizumab, (4) IL15-GPC3 chimeric antigen receptor T cells, (5) vincristine/irinotecan, (6) lenvatinib, and (7) pembrolizumab. Here, GPC3 is linked to hepatocellular carcinoma.